Find information on thousands of medical conditions and prescription drugs.

Isotretinoin

Isotretinoin is a generic medication used for the treatment of severe acne and most commonly known under the brands Accutane and Roaccutane. It is a retinoid, meaning it is derived from vitamin A and is found naturally in the body, produced by the liver in small quantities. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
Ibuprofen
Idarubicin
Idebenone
IFEX
Iloprost
Imatinib mesylate
Imdur
Imipenem
Imipramine
Imiquimod
Imitrex
Imodium
Indahexal
Indapamide
Inderal
Indocin
Indometacin
Infliximab
INH
Inosine
Intal
Interferon gamma
Intralipid
Invanz
Invirase
Iontocaine
Iotrolan
Ipratropium bromide
Iproniazid
Irbesartan
Iressa
Irinotecan
Isocarboxazid
Isoflurane
Isohexal
Isoleucine
Isomonit
Isoniazid
Isoprenaline
Isordil
Isosorbide
Isosorbide dinitrate
Isosorbide mononitrate
Isotretinoin
Itraconazole
Ivermectin
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

History

Prior to the development of isotretinoin, the mainstay treatment of severe acne was oral antibiotics such as the tetracyclines and erythromycin. While these drugs have proven efficacy, they worked against only one contributing factor of acne, Propionibacterium acnes bacteria. The antibiotics gradually became less effective over time as more resistant strains of the bacterium became prominent.

An early, effective treatment of acne was high doses of the fat soluble vitamin A. At these dose levels (sometimes 500,000 IU per day) effects such as reduced production of sebum and dry hair could be noticed. However the vitamin also had many other prominent side effects which inhibited its widespread use.

The development of the derivative of retinoic acid, isotretinoin (13-cis-retinoic acid), and its release in 1982 by Hoffmann-La Roche was a great step forward in the treatment of acne. The synthetic compound provided better therapeutic benefit than vitamin A, while also producing fewer side effects. In February 2002 Roche's patents for isotretinoin expired, there are now many other companies selling cheaper generic versions of the drug.

Today isotretinoin is usually prescribed after other acne treatments have failed to produce results. The treatment of acne usually begins with topicals, moves onto oral antibiotics (or a combination) and finally isotretinoin therapy. This is because other treatments, while less effective than isotretinoin, produce far fewer side effects.

Brand names

Isotretinoin is produced under many brand names by many manufacturers. It is available typically as 5 mg, 10 mg, 20 mg and (in the USA) 40 mg capsules.

Some brands of isotretinoin include:

  • Accure® by Alphapharm
  • Accutane® and Roaccutane® by Roche
  • Aknenormin® by Hermal
  • Amnesteem® by Mylan
  • Ciscutan® by Pelpharma
  • Claravis® by Barr
  • Isohexal® by Hexal Australia
  • Isotroin® by Cipla
  • Oratane® by Douglas Pharmaceuticals
  • Sotret® by Ranbaxy

Indications

Isotretinoin is indicated for treatment for a number of dermatological conditions, most commonly acne. It is generally not used as a first-line treatment due to the potential side effects. Antibiotics (such as the tetracyclines) are usually prescribed before isotretinoin.

Severe forms of acne (conglobata, fulminans and nodulocystic) as well as acne that scars can be successfully treated with isotretinoin.

Acne that has not responded to other treatment will usually respond to isotretinoin. Dysmorphophobic patients may also be prescribed isotretinoin.

Read more at Wikipedia.org


[List your site here Free!]


Disseminate and recurrent infundibulofolliculitis: response to isotretinoin
From Journal of Drugs in Dermatology, 7/1/04 by K. Aroni

Abstract

Disseminate and recurrent infundibulofolliculitis (DRIF) is a rarely-reported disorder. Here, the authors describe a case in which isotretinoin was successfully used to treat DRIF.

**********

Case Report

A 60-year-old white woman presented with a diffuse erythematous follicular rash 2-mm in size. She reported experiencing intense pruritus that had begun seven months previously and was initially located on her trunk. Seasonal association, constitutional symptoms, personal or family history of any other skin or systemic disease was not reported. The physical examination and laboratory tests including full blood count, biochemical profile, and urinary analysis were all normal. The patient reported that the onset of her symptoms was abrupt and occurred immediately after polishing a wooden surface at the fireplace of her house. The skin biopsy taken by 4-mm punch showed foci of necrosis with adjacent collection of polymorphonuclear leukocytes in the infundibulum and few lymphocytes around the blood vessels (Figure 1).

The patient had received corticosteroids locally and hydroxyzine orally in the past, without any response. We put the patient on 10 mg of isotretinoin per day orally for 15 days and then increased the dose to 30 mg for two additional months. During this period, the patient significantly improved, but there were still some lesions and mild pruritus so we advised her to change the lacquer she was using on her furniture. Remission was achieved 45 days after the beginning of therapy. One year after the end of treatment, the individual continues to remain free of symptoms.

[FIGURE 1 OMITTED]

Discussion

Disseminate and recurrent infundibulofolliculitis, described first by Hitch and Lund, is a rare disease affecting mostly black men, usually less than 40 years of age (1). The list of all presently reported cases is rather short; the total number is as high as 24 (1-12).

The case described here was that of a 60-year-old white woman. This case was the second one of DRIF in which we administered isotretinoin (13-cis retinoic acid) successfully. Our previous case was that of a 30-year-old white man that received isotretinoin 0.6 mg/kg/day orally for four months. His response was successful starting one month after the beginning of treatment. This man returned to us three years later with a relapse that occurred after browsing a few times in furniture shops (while three years ago he did not mention a similar event). We believe that some association exists between furniture lacquer and DRIF, possibly the former belonging to a category of precipitating factors. In the present case, a lower dose of isotretinoin was administered and the response started 45 days after the onset of treatment. The case described in this report responded successfully, even with a lower dose of isotretinoin.

References

1. Hitch JM, Lund HZ. Disseminated and recurrent infundibulo-folliculitis, Report of a case. Arch Dermatol 1968; 97:432-435.

2. Thew MA, Wood MG. Disseminated and recurrent infundibulo-folliculitis, Report of a case. Arch Dermatol 1969; 100:728-733.

3. Wolf M. Tolmach J. Disseminated and recurrent infundibulo-folliculitis. Arch Dermatol 1971; 103:552-553.

4. Kaidbey KH, Farah FS, Matta MT. Disseminated and recurrent infundibulo-folliculitis, Report of two cases. Dermatologica 1971; 143:29-35.

5. Hitch JM, Lund HZ. Disseminated and recurrent infundibulo-folliculitis. Arch Dermatol 1972; 105:580-583.

6. Soyinka F. Recurrent disseminated infundibulofolliculitis. Int J Dermatol 1973; 12(5):314-317.

7. Owen WR, Wood C. Disseminate and recurrent infundibulofolliculitis. Arch Dermatol. 1979; 115(2):174-175.

8. Karg E. Kiss A. Schneider I. Recurrent disseminated infundibulofolliculitis. Hautarzt 1986; 37(3):156-158, German.

9. Aroni K. Aivaliotis M. Davaris P. Disseminate and Recurrent Infundibular folliculitis (D.R.I.F): Report of a case succesfully treated with Isotretinoin. J Dermatol 1998; 25:51-53.

10. Ravikumar BC, et al. Disseminate and recurrent infundibulofolliculitis: response to psoralen plus UVA therapy. Int J Dermatol 1999; 38(1):75-76.

11. Calka O. Metin A. Ozen S. A case of disseminated and recurrent infundibulofolliculitis responsive to treatment with systemic isotretinoin. J Dermatol 2002; 29(7):431-434.

12. Heymann WR. Infundibulofolliculitis of the neck. Cutis 2002; 70(3):178-180.

K ARONI MD, A GRAPSA MD, E AGAPITOS MD

ASSOCIATE PROFESSOR IN PATHOLOGY, DEPARTMENT OF PATHOLOGY, MEDICAL SCHOOL

THE NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, ATHENS, GREECE

ADDRESS FOR CORRESPONDENCE:

K. Aroni MD

Department of Pathology, Medical School

The National and Kapodistrian University of Athens

Mikras Asias 75 Street

GR-115 27 Athens

Greece

Phone: +30210-7462177

CASE REPORT CONTEST

THE JOURNAL OF DRUGS IN DERMATOLOGY IS PLEASED TO ANNOUNCE AN ONGOING DERMATOLOGY CASE REPORT CONTEST, OPEN TO RESIDENTS, FELLOWS, AND PRACTICING PHYSICIANS.

IN EACH ISSUE OF THE JOURNAL, SIX WINNING CASE REPORTS--AS JUDGED BY A LEADING PANEL OF DERMATOLOGISTS--WILL BE PUBLISHED IN THIS SECTION, WITH THE WINNERS RECEIVING A COMPLIMENTARY ONE-YEAR SUBSCRIPTION TO THE JOURNAL OF DRUGS IN DERMATOLOGY.

WINNERS WILL BE SELECTED BASED ON NOVELTY, RELEVANCE, AND OVERALL QUALITY OF THEIR SUBMISSIONS, AND MULTIPLE ENTRIES ARE ENCOURAGED. FULL RULES AND AN ENTRY FORM CAN BE FOUND ON THE LAST PAGE OF THE JOURNAL, OR ONLINE AT WWW.DRUGSINDERMATOLOGY.COM.

COPYRIGHT 2004 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group

Return to Isotretinoin
Home Contact Resources Exchange Links ebay